Health ยท DR Congo

WHO Experts Recommend Two More Vaccine Candidates for Ebola Trial in DR Congo

The World Health Organization says its expert groups have recommended adding two Bundibugyo-specific vaccine candidates, from Oxford/Serum Institute and Moderna, to the Tomayni trial in DR Congo. They will be tested once national approvals are granted, as the outbreak has passed 10,000 reported cases.

The World Health Organization (WHO) says its expert groups have recommended adding two new vaccine candidates to the Tomayni clinical trial under way in the Democratic Republic of Congo, where an Ebola outbreak is continuing.

The candidates are ChAdOx1 BDBV, developed by the University of Oxford with India's Serum Institute, and mRNA-1469, made by the US company Moderna. The WHO said the recommendation means vaccines designed specifically against the Bundibugyo strain, which is behind the current outbreak, will be evaluated for the first time during an outbreak of the disease. An independent advisory group based its advice on pre-clinical evidence from laboratory and animal studies, along with early clinical data. The vaccines will join the trial once national approvals are granted.

The trial is led by Congo's National Institute for Biomedical Research with the University of Antwerp, in collaboration with the WHO and other partners. The Coalition for Epidemic Preparedness Innovations (CEPI) is funding development of the candidates. It uses ring vaccination, which targets contacts of confirmed cases, and four rings have been set up so far.

The trial began last month with Ervebo, the only licensed Ebola vaccine, which is approved against the Zaire strain rather than Bundibugyo. The first participants were vaccinated in Bunia, the capital of Ituri province and the centre of the outbreak. Pregnant women and children over 12 are included.

WHO Director-General Tedros Adhanom Ghebreyesus said vaccines alone would not end the outbreak but could become a powerful new tool. He reported more than 10,000 cases and 5,000 deaths, with transmission slowing in some areas while new hotspots continue to emerge. Kenya has recorded nine cases, including two deaths, and Nigeria one confirmed case. The European Centre for Disease Prevention and Control has cautioned that the figures are still under review and the outbreak may be wider than detected.

Tedros urged countries to lift travel restrictions and stressed that vaccines are no substitute for early care, contact tracing, isolation, safe burials and community trust.

More reporting from Voice of Africans